The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | Important factors to consider when selecting between venetoclax & BTK inhibitors for CLL
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, Royal Melbourne Hospital, Melbourne, Australia, provides an overview of factors to consider when selecting therapy for patients with treatment-naïve chronic lymphocytic leukemia (CLL). Dr Anderson highlights the availability of venetoclax and BTK inhibitors in this disease setting, and further comments on the importance of having a discussion with the patient when making treatment decisions. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
